BERKELEY, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU.OB), announced today that Peter M. Strumph, Chief Executive Officer, will present at the Biotechnology Industry Organization (BIO) Investor Forum on Thursday, October 11, 2007 at 12:30 p.m. Pacific Time at The Palace Hotel in San Francisco, California. Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including data from Nile's recently completed Phase Ia study for its lead compound, CD-NP.
The presentation will be webcast live and can be accessed by visiting the Investor Relations section at http://www.nilethera.com. The webcast will be archived for ninety days. Additional information regarding the BIO Investor Forum can be accessed at http://investorforum.bio.org.
About Nile Therapeutics, Inc.
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing innovative products for the treatment of cardiovascular disease. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide (NO) donating properties.
CD-NP, a novel chimeric natriuretic peptide currently in Phase I
clinical studies for the treatment of heart failure, is a selective NPRB
agonist which, in vivo, has been shown to have potent renal enhancement and
cardiac unloading properties but with minimal hypotensive effects compared
with competitive products. CD-NP is a rationally-designed synthetic peptide
designed to incorporate favorable properties of naturally occurring
natriuretic peptides. Data from Nile's recently completed Phase Ia study in
healthy volunteers confirmed several pre-clinical findings, includin
|SOURCE Nile Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved